As SCD could be a very heterogeneous entity, some features have been appointed as decline risk: onset of subjective decline within 5 years, confirmation of cognitive decline by an informant, and decline-related worries besides of lower amyloid Aß-42 levels, and/or hyperphosphorylated tau changes and/or neurodegeneration presence fulfilling the ATN criteria30–32. Here, MAPT is linked to Schnyder corneal dystrophy.